SEC Form SC 13G/A filed by Ascendis Pharma A/S (Amendment)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 14)*

Ascendis Pharma A/S

(Name of Issuer)

American Depository Shares representing Ordinary Shares of Ascendis Pharma A/S

(Title of Class of Securities)

04351P101

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 04351P101

¹ The Reporting Person is the beneficial owner of 10,107,400 of the Issuer’s American Depository Shares (“ADSs”) representing 10,107,400 of the Issuer’s ordinary shares. The percentage calculation assumes that there are currently 57,656,568 outstanding ordinary shares of the Issuer, based on the Issuer’s Form 6-K as filed with the Securities and Exchange Commission (“SEC”) on November 7, 2023.

CUSIP No. 04351P101

² The Reporting Person is the beneficial owner of 10,107,400 of the Issuer’s American Depository Shares (“ADSs”) representing 10,107,400 of the Issuer’s ordinary shares. The percentage calculation assumes that there are currently 57,656,568 outstanding ordinary shares of the Issuer, based on the Issuer’s Form 6-K as filed with the SEC on November 7, 2023.

CUSIP No. 04351P101

³ The Reporting Person is the beneficial owner of 10,107,400 of the Issuer’s American Depository Shares (“ADSs”) representing 10,107,400 of the Issuer’s ordinary shares. The percentage calculation assumes that there are currently 57,656,568 outstanding ordinary shares of the Issuer, based on the Issuer’s Form 6-K as filed with the SEC on November 7, 2023.

CUSIP No. 04351P101

⁴ The Reporting Person is the beneficial owner of 10,107,400 of the Issuer’s American Depository Shares (“ADSs”) representing 10,107,400 of the Issuer’s ordinary shares. The percentage calculation assumes that there are currently 57,656,568 outstanding ordinary shares of the Issuer, based on the Issuer’s Form 6-K as filed with the SEC on November 7, 2023.

CUSIP No. 04351P101

Item 1.

Ascendis Pharma A/S (the “Issuer”).

Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.

Item 2.

The names of the persons filing this report (collectively, the “Reporting Persons”) are:

RA Capital Management, L.P. (“RA Capital”) 

Peter Kolchinsky 

Rajeev Shah  

RA Capital Healthcare Fund, L.P. (the “Fund”)

The principal business office of the Reporting Persons is c/o RA Capital Management, L.P., 200 Berkeley Street, 18^th Floor, Boston, MA 02116.

RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

American Depositary Shares (“ADSs”) of the Issuer.

04351P101

Not applicable.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G/A. The ownership percentages reported are based on 57,656,568 outstanding ordinary shares, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on November 7, 2023.

CUSIP No. 04351P101

The Fund directly holds 10,107,400 of the Issuer’s American Depository Shares (“ADSs”) representing 10,107,400 of the Issuer’s ordinary shares.

RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolios, including the Issuer’s Ordinary Shares reported herein.  Because the Fund has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

Not applicable.

Not applicable.

Item 7.                     Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not applicable.

Not applicable.

Not applicable.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

CUSIP No. 04351P101

Exhibit List

Exhibit 1: Joint Filing Agreement

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date:      February 14, 2024